Shifting the momentum in the multistate litigation over average wholesale pricing for pharmaceuticals, Alabama's Supreme Court, in an opinion that details the 30-year history of state and national drug pricing policy, ruled Friday there was no basis for the state's fraud claims against three drug companies appealing adverse jury verdicts. The ruling wipes out verdicts of $33 million against Novartis, $81 million against GlaxoSmithKline, and $215 million (reduced post-trial to $160 million) against AstraZeneca.
In Blockbuster Ruling, Ala. Supreme Court Overturns Pricing Fraud Verdicts Against Drug Companies
The American Lawyer
October 19, 2009